CAR T-Cell Therapy Kymriah Now Approved for Adult Diffuse Large B-Cell Lymphoma
- Urciuoli B. FDA approves CAR-T cell therapy for diffuse large B-cell lymphoma. Cure Today. Available at https://www.curetoday.com/articles/fda-approves-cart-cell-therapy-for-diffuse-large-b-cell-lymphoma. Accessed 5/9/18.
- FDA expands approval of Kymriah to include relapsed or refractory large B-cell lymphoma. Healio. Available at https://www.healio.com/hematology-oncology/lymphoma/news/online/%7B6907d61c-5cc5-4b95-a2c7-3c4b5464f90f%7D/fda-expands-approval-of-kymriah-to-include-relapsed-or-refractory-large-b-cell-lymphoma. Accessed 5/9/18.
- CAR T cells: engineering patients’ immune cells to treat their cancers, National Cancer Institute. Available at https://www.cancer.gov/about-cancer/treatment/research/car-t-cells. Accessed 5/9/18.
- Narasimhan V. Novartis CTL019 – JULIET data on DLBCL, Investor call. Available at https://www.novartis.com/sites/www.novartis.com/files/2017-06-ir-call-ctl019-dlbcl-juliet-presentation.pdf. Accessed 5/9/18.
- Kymriah product website, Novartis Pharmaceuticals. Available at https://www.us.kymriah.com/acute-lymphoblastic-leukemia-children/interested-in/treatment-information/. Accessed 5/9/18.
- Crump M, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017 Oct 19;130(16):1800-1808. doi: 10.1182/blood-2017-03-769620. Epub 2017 Aug 3.
- Crump M, Et al. Outcomes in refractory aggressive diffuse large b-cell lymphoma (DLBCL): Results from the international SCHOLAR-1 study. Journal of Clinical Oncology 2016 34:15_suppl, 7516-7516.
- Kymriah prescribing information, Novartis Pharmaceuticals. Available at https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/kymriah.pdf. Accessed 5/9/18.